4,6-Disubstituted pyrimidine-based microtubule affinity-regulating kinase 4 (MARK4) inhibitors: synthesis, characterization, <i>in-vitro</i> activity and <i>in-silico</i> studies.

导出 LinkOut

翻译打印收藏纠错

作者： Ashanul,Haque ^[1] ; Khalaf M,Alenezi ^[1] ; Mohd Saeed Maulana Abdul,Rasheed ^[2] ; Md Ataur,Rahman ^[3] ; Saleha,Anwar ^[4] ; Shahzaib,Ahamad ^[5] ; Dinesh,Gupta ^[5]

作者单位： Department of Chemistry, College of Science, University of Hail, Ha'il, Saudi Arabia. ^[1] Department of Biology, College of Science, University of Hail, Ha'il, Saudi Arabia. ^[2] Chemistry Program, New York University Abu Dhabi (NYUAD), Abu Dhabi, United Arab Emirates. ^[3] Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India. ^[4] Translational Bioinformatics Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India. ^[5]

关键词 Alzheimer’s disease kinase inhibitors mark 4 pyrimidine synthesis

DOI 10.3389/fphar.2024.1517504

PMID 39902071

发布时间 2025-02-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in pharmacology

2024年15卷

1517504页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

4,6-Disubstituted pyrimidine-based microtubule affinity-regulating kinase 4 (MARK4) inhibitors: synthesis, characterization, <i>in-vitro</i> activity and <i>in-silico</i> studies.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

4,6-Disubstituted pyrimidine-based microtubule affinity-regulating kinase 4 (MARK4) inhibitors: synthesis, characterization, <i>in-vitro</i> activity and <i>in-silico</i> studies.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

检索历史清除